| abstract |
The invention relates to benzazine or (1-benzyl-1H-indazol-3-yl) -oxyacetic acid, which, when administered in a suitable form to achieve therapeutic tissue levels, results in reduced cataracts. In particular, the lysine salts of bendazac are suitable for the treatment of cataracts, determining appropriate tissue levels both after oral administration and in the treatment of the eye. The invention also relates to the chemical and physical characteristics of the salts of bendazac and the methods for its preparation. |